(CARA) Cara Therapeutic - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1407551092

CARA: Chronic Pain Relief, Pruritus Treatment, Dialysis Pain Management

Cara Therapeutics, Inc. (NASDAQ:CARA) is a biopharmaceutical company specializing in the development of innovative therapeutics for chronic pruritus, a condition characterized by severe itching that can significantly impact quality of life. The companys lead product, KORSUVA (difelikefalin) injection, is approved for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. This product addresses a significant unmet medical need, as pruritus in CKD patients is often resistant to conventional treatments.

In addition to KORSUVA, Cara Therapeutics is advancing Oral difelikefalin, which is currently in Phase II/III clinical trials for the treatment of chronic pruritus associated with notalgia paresthetica, a condition causing intense itching near the spine. The company has established strategic partnerships to expand its global reach, including agreements with Maruishi Pharmaceutical Co., Ltd. for the development of difelikefalin-based products in Japan, Vifor Fresenius Medical Care Renal Pharma Ltd. for the commercialization of KORSUVA in dialysis patients, and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of difelikefalin products in South Korea.

Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. The company has established itself as a leader in the development of peripherally acting kappa opioid receptor agonists, a novel approach to treating pruritus without the central nervous system side effects associated with traditional opioid therapies.

Ticker Symbol: CARA Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Pharmaceuticals Average Volume 20d: 15993 Last Price: 4.92 SMA 20: 4.97 SMA 50: 4.99 SMA 200: 4.39 ATR: 0.36 Market Cap: 22.12M USD P/E: 0.00 P/E Forward: 0.00 P/B: 29.10 P/S: 2.55 RoE: None 3-Month Forecast: Based on and , Cara Therapeutics (CARA) is expected to experience moderate volatility in the near term. The stock is trading near its 20-day and 50-day moving averages, with support levels around $4.90. The relatively low ATR of 0.36 suggests reduced price movement. However, the high P/B ratio of 29.10 and P/S ratio of 2.55 indicate potential overvaluation. Over the next three months, CARA may face headwinds due to its high valuation metrics, potentially leading to a slight downward correction. Support from its 200-day SMA at $4.39 could limit significant declines, but the lack of earnings and profitability may weigh on investor sentiment. Overall, the forecast suggests a sideways to slightly bearish trend.

Additional Sources for CARA Stock

CARA Stock Overview

Market Cap in USD 22m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2014-01-31

CARA Stock Ratings

Growth 5y -85.4%
Fundamental -21.7%
Dividend 0.0%
Rel. Strength Industry -46.1
Analysts 3/5
Fair Price Momentum 2.90 USD
Fair Price DCF -

CARA Dividends

No Dividends Paid

CARA Growth Ratios

Growth Correlation 3m 23.1%
Growth Correlation 12m -37.4%
Growth Correlation 5y -94%
CAGR 5y -46.59%
CAGR/Max DD 5y -0.47
Sharpe Ratio 12m -0.53
Alpha -50.79
Beta 0.15
Volatility 70.27%
Current Volume 2.6k
Average Volume 20d 12.3k
What is the price of CARA stocks?
As of March 15, 2025, the stock is trading at USD 5.13 with a total of 2,562 shares traded.
Over the past week, the price has changed by +4.27%, over one month by -1.35%, over three months by +65.70% and over the past year by -45.65%.
Is Cara Therapeutic a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Cara Therapeutic is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -21.65 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CARA as of March 2025 is 2.90. This means that CARA is currently overvalued and has a potential downside of -43.47%.
Is CARA a buy, sell or hold?
Cara Therapeutic has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold CARA.
  • Strong Buy: 0
  • Buy: 0
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CARA stock price target?
According to ValueRays Forecast Model, CARA Cara Therapeutic will be worth about 3.1 in March 2026. The stock is currently trading at 5.13. This means that the stock has a potential downside of -38.79%.
Issuer Forecast Upside
Wallstreet Target Price 12 133.9%
Analysts Target Price 12.1 136.3%
ValueRay Target Price 3.1 -38.8%